A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
This study has been terminated.
( The biological effect seen with natalizumab was not sufficient to warrant further development in RA. )
Information provided by Elan Pharmaceuticals
First Received on January 27, 2009.
No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study: